

Agreement(s) Filed; Jacksonville Port Authority/Macmillan Bloedel Building Materials Terminal Agreement

The Federal Maritime Commission hereby gives notice of the filing of the following agreement(s) pursuant to section 5 of the Shipping Act of 1984.

Interested parties may inspect and obtain a copy of each agreement at the Washington, DC Office of the Federal Maritime Commission, 1100 L Street, NW., room 10220. Interested parties may submit comments on each agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days after the date of the **Federal Register** in which this notice appears. The requirements for comments are found in § 572.603 of title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

Agreement no: 224-200442.

Title: Jacksonville Port Authority/Macmillan Bloedel Building Materials Terminal Agreement.

Parties: Jacksonville Port Authority (Port) Macmillan Bloedel Building Materials (MBBM).

Synopsis: The Agreement provides the warfage terms and the charges MBBM will pay the Port on forest products moving through certain facilities at the Port's Talleyrand Docks and Terminal.

By Order of the Federal Maritime Commission.

Dated: November 16, 1990.

Joseph C. Polking,
Secretary.

[FR Doc. 90-27387 Filed 11-20-90; 8:45 am]
BILLING CODE 6730-01-M

Filing and Effective Date of Agreement

The Federal Maritime Commission hereby gives notice that on November 13, 1990, the following agreement was filed with the Commission pursuant to section 5 of the Shipping Act of 1984 and was considered effective that date to the extent it constitutes an assessment agreement as described in paragraph (d) of section 5, Shipping Act of 1984.

Agreement No: 224-000084-002.

Title: Pacific Maritime Association Assessment Agreement.

Parties: Members of the Pacific Maritime Association.

Synopsis: The Agreement amends and restates the basic agreement concerning assessments paid to the International Longshoremen's and Warehousemen's Union and Pacific Maritime Association employee benefit costs. The Agreement clarifies the basic agreement's terms

and conditions, leaving the basic assessment formula in place.

Dated: November 15, 1990.

By Order of the Federal Maritime Commission.

Joseph C. Polking,
Secretary.

[FR Doc. 90-27352 Filed 11-20-90; 8:45 am]
BILLING CODE 6730-01-M

Agreement(s) Filed; State of Hawaii/Puget Sound Tug & Barge Co.

The Federal Maritime Commission hereby gives notice of the filing of the following agreement(s) pursuant to section 5 of the Shipping Act of 1984.

Interested parties may inspect and obtain a copy of each agreement at the Washington, DC Office of the Federal Maritime Commission, 1100 L Street NW., room 10220. Interested parties may submit comments on each agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days after the date of the **Federal Register** in which this notice appears. The requirements for comments are found in § 572.603 of title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

Agreement No.: 224-011004-001

Title: State of Hawaii/Puget Sound Tug & Barge Company, dba Hawaiian Marine Lines Terminal Agreement.

Parties:

State of Hawaii
Puget Sound Tug & Barge Company,
dba Hawaiian Marine Lines.

Synopsis: The Agreement reflects the deletion of an area of 578 square feet from leased premises at Honolulu Harbor, Oahu, Hawaii and a reduction in annual rent from \$22,184.00 to \$19,390.00.

Dated: November 15, 1990.

By Order of the Federal Maritime Commission.

Joseph C. Polking,
Secretary.

[FR Doc. 90-27351 Filed 11-20-90; 8:45 am]
BILLING CODE 6730-01-M

Agreement(s) Filed; Vessel Operators Hazardous Materials Association, et al.

The Federal Maritime Commission hereby gives notice of the filing of the following agreement(s) pursuant to section 5 of the Shipping Act of 1984.

Interested parties may inspect and obtain a copy of each agreement at the Washington, DC Office of the Federal

Maritime Commission, 1100 L Street, NW., room 10325. Interested parties may submit comments on each agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days after the date of the **Federal Register** in which this notice appears. The requirements for comments are found in § 572.603 of title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

Agreement No.: 203-011290-003.

Title: Vessel Operators Hazardous Materials Association Agreement.

Parties:

America-Africa-Europe Line GMBH
Atlantic Container Line B.V.
Evergreen Marine Corporation
(Taiwan), Ltd.
Farrell Lines, Inc.
Hamburg-Sudamerikanische
Dampfschiffahrts Gesellschaft
Eggert & Amsinck (Columbus Line)
Hapag-Lloyd AG
Independent Container Line Ltd.
Kawasaki Kisen Kaisha Ltd.
Mitsui O.S.K. Lines, Ltd.
A.P. Moller-Maersk Line
Neddlloyd Lijnen B.V.
Nippon Yusen Kaisha Line
P&O Containers, Ltd.
Sea-Land Service, Inc.
Wilh. Wilhelmsen Ltd. AS
Zim Israel Navigation Co., Ltd.

Synopsis: The proposed amendment would add Crowley Maritime Corporation as a party to the Agreement. The parties have requested a shortened review period.

Dated: November 15, 1990.

By Order of the Federal Maritime Commission.

Joseph C. Polking,
Secretary.

[FR Doc. 90-27349 Filed 11-20-90; 8:45 am]
BILLING CODE 6730-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Assistant Secretary for Health

Advisory Committee on the Food and Drug Administration; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), notice is hereby given that the Advisory Committee on the Food and Drug Administration (FDA) will hold a meeting on Monday, December 17, 1990 from 8:30 a.m. to 5

p.m. and Tuesday, December 18, 1990 from 8:30 a.m. to 1 p.m. The meeting is open to the public and will be held in the Clark Room of the Holiday Inn Capitol Hill located at 550 C Street, SW., Washington, DC 20005. Public registration will begin one half hour prior to the beginning of the meeting on each day.

The purpose of this meeting is to discuss the results of the Subcommittee meetings which took place this Fall. The Committee will identify crosscutting issues, that have an impact on the mission, structure, and responsibilities of FDA, including resource questions such as facilities, personnel, and field and enforcement issues, for further discussion.

FOR FURTHER INFORMATION CONTACT: Sheryl Rosenthal, Advisory Committee on the Food and Drug Administration, Department of Health and Human Services, room 740-G Humphrey Building, 200 Independence Avenue, SW., Washington DC 20201. Telephone number (202) 245-7305.

Dated: November 14, 1990.

Eric M. Katz,

Executive Secretary, Advisory Committee on the FDA.

[FR Doc. 90-27345 Filed 11-20-90; 8:45 am]

BILLING CODE 4160-01-M

Food and Drug Administration

[Docket No. 90F-0363]

Ciba-Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba-Geigy Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe and expanded use of calcium bis[monoethyl(3,5-di-*tert*-butyl-4-hydroxybenzyl) phosphonate] as a stabilizer for low density polyethylene and olefin copolymers.

FOR FURTHER INFORMATION CONTACT: Julius Smith, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP OB4229) has been filed by Ciba-Geigy Corp., Seven Skyline Dr., Hawthorne, NY 10532-2188. The petition proposes to amend the food additive regulations in

§178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) to provide for the safe and expanded use of calcium bis[monoethyl(3,5-di-*tert*-butyl-4-hydroxybenzyl)phosphonate] as a stabilizer for low density polyethylene and olefin copolymers complying with 21 CFR 177.1520.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated November 14, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90-27374 Filed 11-20-90; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 90F-0364]

Ciba-Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba-Geigy Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of *N,N*-bis(2-ethylhexyl)-*ar*-methyl-*lH*-benzotriazole-*l*-methanamine as a copper deactivator for lubricants.

FOR FURTHER INFORMATION CONTACT: Julius Smith, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 1B4233) has been filed by Ciba-Geigy Corp., Seven Skyline Drive, Hawthorne, NY 10532-2188. The petition proposes to amend the food additive regulations in § 178.3570 *Lubricants with incidental food contact* (21 CFR 178.3570) to provide for the safe use of *N,N*-bis(2-ethylhexyl)-*ar*-methyl-*lH*-benzotriazole-*l*-methanamine as a copper deactivator for lubricants complying with 21 CFR 178.3570.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and

this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: November 14, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90-27372 Filed 11-20-90; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 90F-0350]

Ciba-Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba-Geigy Corp. has filed a petition proposing that the food additive regulations be amended to provide for the additional safe uses of hexamethylene bis(3,5-di-*tert*-butyl-4-hydroxyhydrocinnamate) as a stabilizer in various polymers intended for food-contact use.

FOR FURTHER INFORMATION CONTACT: Richard H. White, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP OB4227) has been filed by Ciba-Geigy Corp., Seven Skyline Dr., Hawthorne, NY 10532-2188. The petition proposes to amend the food additive regulations in § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) to provide for the additional use of hexamethylene bis(3,5-di-*tert*-butyl-4-hydroxyhydrocinnamate) as a stabilizer in polymers complying with 21 CFR 175.105, 175.125, 175.300, 175.320, 176.170, 176.180, 177.1210, 177.2600, 178.3800, and 178.3850, respectively.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: November 14, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90-27373 Filed 11-20-90; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 90N-0394]

Drug Export; Minitran® (Nitroglycerin) Transdermal System

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that 3M Pharmaceuticals has filed an application requesting approval for the export of the human drug Minitran® (nitroglycerin) Transdermal System to France, Italy, and New Zealand.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Frank R. Fazzari, Division Drug Labeling Compliance (HFD-313), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8073.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the *Federal Register* within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that 3M Pharmaceuticals, 3M Center Bldg. 270-3A-01, St. Paul, MN 55144-1000, has filed an application requesting approval for the export of the drug Minitran®

(nitroglycerin) Transdermal System, to France, Italy, and New Zealand. This product is used for the prevention of angina pectoris due to coronary artery disease. The application was received and filed in the Center for Drug Evaluation and Research on September 17, 1990, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by December 3, 1990, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Drug Evaluation and Research (21 CFR 5.44).

Dated: November 6, 1990.

Daniel L. Michels,

Director, Office of Compliance, Center for Drug Evaluation and Research.

[FR Doc. 90-27375 Filed 11-20-90; 8:45 am]

BILLING CODE 4160-01-M

Health Care Financing Administration

[BPO-081-N]

Medicare Program; Establishing Procedures for Transmitting Information Between Medicare Carriers and Medicare Supplemental Insurers

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: General notice.

SUMMARY: This notice announces and describes the procedure for the automatic transfer of claims information from Medicare carriers to Medicare supplemental (Medigap) insurers when a beneficiary has assigned his or her right of payment to a participating physician or supplier. It delineates the roles of the Medicare carriers, Medigap insurers, State insurance departments, beneficiaries, physicians and suppliers, and HCFA.

The procedure for the automatic transfer of claims is required by section 1842(h)(3)(B) of the Social Security Act, as added by section 4081(a) of the Omnibus Budget Reconciliation Act of 1987 and is intended to speed payment of Medicare supplemental insurance benefits to participating physicians and suppliers.

EFFECTIVE DATE: This procedure is effective for dates of service on or after January 1, 1989, as set by statute (Pub. L. 100-203).

FOR FURTHER INFORMATION CONTACT:

Telephone inquiries: Joan Kral, (301) 966-7160.

Written inquiries: Marc Thomas, Health Care Financing Administration, Bureau of Program Operations, 367 Meadows East Building, 6325 Security Boulevard, Baltimore, Maryland 21207.

SUPPLEMENTARY INFORMATION:

I. Background

A. Medicare Supplemental Policies

The Medicare program consists of two separate but complementary insurance programs, a Hospital Insurance Benefits program, known as part A, and a Supplementary Medical Insurance program, known as part B. The Medicare program was not designed to cover the total cost of providing medical care for its beneficiaries. Both parts A and B have deductible and coinsurance cost sharing provisions. Also, there are a number of items not covered under either of Medicare's two insurance programs such as custodial nursing home care, dental care, and eyeglasses. Beneficiaries may either pay the full cost of these services out-of-pocket or may choose to purchase additional private insurance to help pay the costs.

Nearly two-thirds of all Medicare beneficiaries have some type of private health insurance coverage in addition to Medicare. This coverage includes Medicare supplemental policies, employer sponsored health plans, as well as limited benefit plans such as indemnity policies, specified disease coverage and long-term care policies.

Medicare supplemental policies are designed to fill specific gaps in the Medicare benefit structure. These policies typically offer coverage of some or all of Medicare's deductible and coinsurance amounts and sometimes include coverage of services not covered under Medicare. There are many varieties of supplemental policies with premiums and benefit structures designed to meet the needs of people with a variety of incomes. A characteristic of most of these policies,